Form 4: Regeneron EVP Marion McCourt Executes Stock Option and Sells Shares Under 10b5-1 Plan
SEC Form 4
Marion McCourt, EVP Commercial at Regeneron Pharmaceuticals, exercised stock options and sold 1,000 shares of common stock on October 1, 2024, under a pre-arranged 10b5-1 trading plan.
Summary
- Marion McCourt, EVP Commercial at Regeneron Pharmaceuticals, executed a transaction involving the company's stock on October 1, 2024.
- McCourt exercised a non-qualified stock option to acquire 1,000 shares of common stock at a price of $381.4 per share.
- Simultaneously, McCourt sold 1,000 shares of common stock at a price of $1,054.06 per share.
- These transactions were executed under a pre-arranged trading plan intended to comply with Rule 10b5-1(c), which was adopted on February 13, 2024.
- Following these transactions, McCourt directly owns 12,931 shares of Regeneron common stock and indirectly owns 174 shares through a 401(k) plan.
- McCourt also holds options to purchase 7,000 shares of Regeneron common stock.
Sentiment
Score: 6
Explanation: The document reflects routine executive stock transactions under a pre-arranged plan. It doesn't indicate any significant positive or negative developments for the company.
Future Outlook
The document does not contain specific forward-looking statements, but the ongoing execution of the 10b5-1 trading plan suggests continued transactions in the future.
Industry Context
Executive stock transactions are common in the pharmaceutical industry as part of compensation packages. The use of 10b5-1 plans is a standard practice to allow insiders to trade company stock while avoiding accusations of insider trading.
Comparison to Industry Standards
- Executive compensation packages in the pharmaceutical industry typically include a mix of salary, stock options, and restricted stock units.
- Companies like Amgen, Gilead Sciences, and Pfizer also utilize stock options and 10b5-1 plans for their executives.
- The vesting schedule of the stock option award (four equal annual installments) is a common practice in the industry.
Stakeholder Impact
- The transactions have a minimal direct impact on shareholders, employees, customers, suppliers, and creditors.
- The stock sale may slightly increase the available float of Regeneron shares.
Key Dates
| Date | Description |
|---|---|
| February 13, 2024 | Date the Rule 10b5-1(c) plan was adopted. |
| October 01, 2024 | Date of stock option exercise and sale of shares. |
| October 02, 2024 | Date of signature on the Form 4. |
| December 12, 2028 | Expiration date of the non-qualified stock option. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.